Paper Details

  1. Home
  2. Paper Details

Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.

Author: CleggA, HewitsonP, ScottD A, SidhuM, WaughN

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Gemcitabine, paclitaxel, and vinorelbine as first line treatment and docetaxel as second line treatment appear to be more beneficial for non-small cell lung cancer than best supportive care and older chemotherapy agents.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Lung cancer remains a devastating disease with few effective treatment options. Recent developments in chemotherapy have led to cautious optimism. This paper reviews the evidence on the clinical and cost effectiveness of four of the new generation drugs for patients with lung cancer. ME...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/thorax.57.1.20

データ提供：米国国立医学図書館（NLM）

Chemotherapy for Non-Small Cell Lung Cancer: Navigating the Desert of Treatment Options

Imagine non-small cell lung cancer (NSCLC) as a formidable sandstorm, a deadly threat to human health. This research, like a courageous expedition seeking a cure, investigates the clinical and cost-effectiveness of four different chemotherapy drugs, paclitaxel, docetaxel, gemcitabine, and vinorelbine, in treating NSCLC.

The researchers, like skilled desert warriors, conducted a systematic review of 33 randomized controlled trials (RCTs) comparing the effectiveness of these chemotherapy drugs with best supportive care (BSC) and older chemotherapy agents. They carefully analyzed data on patient survival, quality of life, and adverse effects, seeking to identify the most effective and cost-effective treatment options.

The findings, like a shimmering oasis in the desert of treatment options, suggest that gemcitabine, paclitaxel, and vinorelbine, when used as first-line treatment, and docetaxel, as second-line treatment, offer a significant survival advantage over BSC and older chemotherapy agents, extending life by 2-4 months. The researchers found that these survival gains did not come at the expense of quality of life and were delivered at reasonable levels of incremental cost-effectiveness.

A Beacon of Hope in the Desert of Lung Cancer

This research underscores the progress made in treating non-small cell lung cancer. The study identifies several chemotherapy drugs that offer a significant survival advantage over BSC and older treatments.

Finding the Right Path in the Desert of Treatment Decisions

This research provides valuable insights for oncologists and patients facing the challenges of non-small cell lung cancer. It emphasizes the importance of carefully considering all treatment options, including the potential benefits, risks, and costs of each.

Dr. Camel's Conclusion

This study highlights the ongoing progress in the fight against non-small cell lung cancer. It's a reminder that, just as a wise camel seeks out the most suitable path through the desert, we must continue to explore new and innovative approaches to treatment, guided by the principles of effectiveness, safety, and cost-effectiveness.

Date :
  1. Date Completed 2002-02-19
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

11809985

DOI: Digital Object Identifier

10.1136/thorax.57.1.20

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.